LIRAFLAME

1. Given written informed consent

2. Male or female patients >50 years with type 2 diabetes (WHO criteria)

3. HbA1c ≥ 48 mmol/mol (6.5 %)

4. eGFR ≥ 30 ml/min/1.73 m2 (estimated by CKD-epi formula)

5. Stable glucose-lowering medication (excluding oral glucocorticoids, calcineurin inhibitors, dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon like peptide-1 agonists and other agents, which in the investigator's opinion could interfere with the effect of liraglutide)for at least 4 weeks before the baseline PET/CT

6. Stable/no treatment of hypercholesterolemia 4 weeks before baseline PET/CT

7. Must be able to communicate with the investigator and understand informed consent.

1. Type 1 diabetes mellitus

2. Chronic pancreatitis / previous acute pancreatitis

3. Known or suspected hypersensitivity to trial product(s) or related products

4. Treatment 90 days prior to screening with oral glucocorticoids, calcineurin inhibitors, dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon like peptide-1 agonists and other agents, which in the investigator's opinion could interfere with the effect of liraglutide

5. Cancer or any other clinically significant disorder, except for conditions associated with type 2 diabetes history, which in the investigators opinion could interfere with the results of the trial

6. Clinical signs of diabetic gastroparesis

7. Previous bowel resection

8. Impaired liver function (transaminases > two times upper reference levels)

9. Inflammatory bowel disease

10. Weight >150 kg

11. Females of childbearing potential who are pregnant, breast-feeding, intend to become pregnant or are not using adequate contraceptive methods

12. Known or suspected abuse of alcohol or narcotics

13. Subjects with personal or family history of medullary thyroid carcinoma or a personal history of multiple endocrine neoplasia type 2